Skip to content

Psilocybin: all studies

Page 77 of 439: studies 761 to 770 of 4,389, newest first. Back to the psilocybin overview

Research

A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.

Psychotherapy January 13, 2025 Roman Palitsky, Jessica L Maples-Keller, Caroline Peacock et al. 13 citations

Psilocybin-assisted therapy (PAT) is an experimental treatment with transformative promise. Developing standards for PAT psychotherapy protocols is a priority, but psychotherapeutic protocol components of PAT have been subjected to little rigorous research. This study was designed to assess protocol components in a trial of PAT. The Enhanced Critical Incident Technique (E-CIT) was used to...

DOI: 10.1037/pst0000551 (opens in new tab) Psychedelic therapy Psilocybin treatment Mental health care Therapeutic protocols +1

Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Randall D Ordovich-Clarkson, Maurice Jabbour, Daniel Arteaga Pelayo et al. 7 citations

Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic pathways. Currently, there are no proven prophylactic approaches to the prevention of PD. This systematic review seeks to compare two separate compounds, metformin (MTF) and psilocybin, as potential prophylactic therapeutics against the development...

DOI: 10.1016/j.pnpbp.2024.111155 (opens in new tab) Full text (opens in new tab) Psilocybin Neurodegenerative disorders neurodegeneration Brain disease Neural degeneration +9

Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Juliana Lima Constantino, Jens H van Dalfsen, Sara Massetti et al. 6 citations

Psilocybin represents a novel therapeutic approach for individuals with major depressive disorder (MDD) who do not respond to conventional antidepressant treatment. Investigating the influence of psilocybin on the pathophysiological processes involved in MDD could enhance our neurobiological understanding of the presumed antidepressant action mechanism. This systematic review aims to summarize...

Cell-type specific transcriptional modulation by psilocybin induces sustained plasticity in mouse medial prefrontal cortex

bioRxiv (Cold Spring Harbor Laboratory) January 8, 2025 Delong Zhou, Heike Schuler, Vedrana Cvetkovska et al. 2 citations preprint

Abstract Despite enormous interest in psychedelics for psychiatric interventions, potential underlying biological mechanisms remain unclear. Here, we confirm that a single dose of psilocybin increases synaptic transmission in mouse medial prefrontal cortex. Using scRNA-sequencing, we identify cell-type specific mechanisms of sustained neuroplastic effects. We show that, 24h post-psilocybin,...

A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy

Journal of Psychoactive Drugs January 7, 2025 Fernando Espí Forcén

As psilocybin awaits approval by the Food and Drug Administration (FDA), scholars debate whether psychedelic-assisted psychotherapy should be required when prescribing this medicine. Here, we report the case of a patient who underwent a psilocybin experience without psychedelic-assisted psychotherapy, resulting in inpatient psychiatric admission. This case underscores the importance of taking...

DOI: 10.1080/02791072.2025.2449918 (opens in new tab) Psilocybin Hallucinogen Psychotherapist Experiential learning

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation

Psychopharmacology January 7, 2025 Mona Irrmischer, Drew J. Puxty, Hessel Engelbregt et al. 4 citations

Abstract Rationale Psychedelic-assisted therapy is increasingly applied within mental health treatment. Objectives This study focused on factors moderating changes in the acute and long-term effects of an individual psilocybin-assisted program on depression, anxiety, PTSD and personality structures by including demographic factors, subjective experience and degree of mystical type experiences...

Single-nucleus transcriptomics reveals time-dependent and cell-type-specific effects of psilocybin on gene expression

bioRxiv (Cold Spring Harbor Laboratory) January 4, 2025 Clara Liao, Ethan O'Farrell, Yaman Qalieh et al. 3 citations preprint

ABSTRACT There is growing interest to investigate classic psychedelics as potential therapeutics for mental illnesses. Previous studies have demonstrated that one dose of psilocybin leads to persisting neural and behavioral changes. The durability of psilocybin’s effects suggests that there are likely alterations of gene expression at the transcriptional level. In this study, we performed...

DOI: 10.1101/2025.01.04.631335 (opens in new tab) Psilocybin Gabaergic Excitatory postsynaptic potential Gene expression +2

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.

General Hospital Psychiatry 2025 Yvan Beaussant, Elise C. Tarbi, Kabir Nigam et al. 3 citations

Psilocybin-assisted therapy (PAT) shows promise for cancer-related depression, yet little research has examined how therapeutic context shapes patient experiences. While set (mindset) and setting (environment) are considered central to psychedelic treatment, empirical evidence on their role in PAT acceptability remains limited. This study explores factors influencing the acceptability of PAT...